GeNeuro enrolls first patient in temelimab Phase 2 multiple sclerosis trial in collaboration with the Karolinska Institutet’s Academic Specialist Center (ASC)
Geneva, Switzerland, June 25, 2020–7:30 amCEST –GeNeuro (Euronext Paris: CH0308403085 -GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune dis ...